Alzheimer’s drug Bapineuzumab fails in Phase 3 clinical trial

Bapineuzumab, an experimental treatment for Alzheimer’s disease, proved ineffective in a large-scale, late-stage clinical trial in people with Alzheimer’s who carry a risk gene known as ApoE4. Researchers said the drug did not improve either cognition or daily functioning of study participants when compared to those who took a placebo. Additional Phase 3 clinical trials of the drug are expected to report results later this year.
Read the article >>
Read the Alzheimer’s Association’s statement >>

http://www.nytimes.com/2012/07/24/business/alzheimers-drug-fails-its-first-clinical-trial.html?_r=1